Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-tubulin is a fundamental structural protein that, along with alpha-tubulin, forms heterodimers which polymerize into microtubules [3, 13, 18]. These microtubules are dynamic filaments essential for maintaining cell shape, enabling intracellular transport, and forming the mitotic spindle during cell division [3, 12, 13, 18]. The taxane binding site is a specific pocket located on the luminal surface of the beta-tubulin subunit within the microtubule polymer [8, 10, 14, 18]. Drugs targeting this site, such as paclitaxel and docetaxel, act as microtubule-stabilizing agents by binding to and stabilizing the lattice, which prevents the dynamic depolymerization necessary for chromosome segregation [3, 8, 9, 14, 18]. This interference leads to mitotic arrest at the G2/M phase and triggers apoptosis, making the taxane site a critical target in the treatment of numerous solid tumors, including breast, lung, and ovarian cancers [1, 3, 14]. However, therapeutic efficacy is often limited by the development of resistance—frequently through mutations in the binding site or the upregulation of specific tubulin isotypes like TUBB3—and by systemic toxicities such as peripheral neuropathy and neutropenia [6, 11, 14, 15, 18].
Binds to the taxane site on the luminal surface of beta-tubulin within microtubules, stabilizing the polymer and inhibiting depolymerization [3, 8, 14]. This disrupts mitotic spindle dynamics, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis [9, 11, 18].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-tubulin (taxane binding site) (TUBB).